Showing 1581-1590 of 1692 results for "".
- Cell and Gene Therapies for Parkinson Disease Moving Forwardhttps://practicalneurology.com/news/cell-and-gene-therapies-for-parkinson-disease-moving-forward/2469615/In an open-label phase 1 clinical study (NCT04802733), researchers successfully administered the first dose of pluripotent stem cell-derived dopaminergic neurons (DA01; Blue Rock Therapeutics, a subsidiery of Bayer Therapeutics, H
- Inebilizumab Provides Long-Term Freedom From Relapse for Neuromyelitis Optica Spectrum Disorderhttps://practicalneurology.com/news/inebilizumab-provides-long-term-freedom-from-relapse-for-neuromyelitis-optica-spectrum-disorder/2469562/Inebilizumab (Uplizna; Horizon Therapeutics, Deerfield, IL), an antiCD19 B cell depleteing antibody is approved by Food and Drug Administration for treatment of antiaquaporin-4 antibody positive (antiAQP4+) neuromyelitis optica spectrum disorder (NMOSD). In clinical trials, inebilizuma
- Cenobamate Provides High Rates of Seizure Freedom and Reductions or Discontinuations of Concomitant Antiseizure Medicationshttps://practicalneurology.com/news/cenobamate-provides-high-rates-of-seizure-freedom-and-reductions-or-discontinuations-of-concomitant-antiseizure-medications/2469559/Cenobamate was approved for treatment of partial onset seizures in May 2020 (Xcopri; SK LIfe Science, Paramus, NJ), and results of open-label extension studies have now been reported. Seizure reduction rates in the 214 people who had at least 1 dose of cenobamate after a 12-week titration period
- Neurovascular Quality Initiative-Quality Outcomes Database and the Society of Vascular and Interventional Neurology Form Alliancehttps://practicalneurology.com/news/neurovascular-quality-initiative-quality-outcomes-database-and-the-society-of-vascular-and-interventional-neurology-form-alliance/2469551/The Society of Neurointerventional Surgery (SNIS) and Neuropoint Alliance (NPA) will be bringing the Society of Vascular and Interventional Neurology (SVIN) to the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD). The alliance is to expand the breadth and depth of the NVQI-QO
- Lasmiditan Provided Freedom From Migraine Pain at 60 Minutes for as Long as 48 Hourshttps://practicalneurology.com/news/lasmiditan-provided-freedom-from-migraine-pain-at-60-minutes-for-as-long-as-48-hours/2469375/In a phase 3 study (NCT02439320) of lasmiditan (Reyvow; Eli Lilly and Company, Indianapolis, IN), which is an approved treatment for migraine with or without aura, participants treated with
- Freedom from Pain and Most Bothersome Symptoms of Migraine With Ubrogepant in Phase 3 Trialhttps://practicalneurology.com/news/freedom-from-pain-and-most-bothersome-symptoms-of-migraine-with-ubrogepant-in-phase-3-trial/2469079/Positive results were achieved in the phase 3 clinical trial that evaluated ubrogepant (Allergan; Madison, NJ) for acute treatment of migraine. The data is published in The Journal of the American Medical Association
- Phase 3 Trial of Fenfluramine for Lennox-Gastaut Syndrome Completes Enrollmenthttps://practicalneurology.com/news/phase-3-trial-of-fenfluramine-for-lennox-gastaut-syndrome-completes-enrollment/2468948/Enrollment of 263 individuals with Lennox-Gastaut syndrome (LGS) has been completed for a phase 3 clinical (NCT03355209) trial of fenfluramine (Fintepla; Zogenix, Emeryville, CA). The primary outcome measure is decreased seizure freque
- Patient Advocacy Organizations Join Forces to Improve Care for Spinal Muscular Atrophyhttps://practicalneurology.com/news/patient-advocacy-organizations-join-forces-to-improve-care-for-spinal-muscular-atrophy/2468796/Patient advocacy organizations are partnering to obtain real-world evidence to advance research, drug development, and access to therapies for children and adults with spinal muscular atrophy (SMA). Cure SMA and Parent Project Muscular Dystrophy (PPMD) will collaborate to aggregate
- Subcutaneous Lecanemab for Alzheimer Disease Maintenance Dosing Now Availablehttps://practicalneurology.com/news/subcutaneous-lecanemab-for-alzheimer-disease-maintenance-dosing-now-available/2483895/Leqembi IQLIK (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA), a formulation of lecanemab approved by the Food and Drug Administration (FDA) for subcutaneous injection for maintenance dosing for people with early Alzheimer disease (AD) including those with mild cognitive impairment (
- Peripheral Nerve Stimulation Reduced Chronic Craniofacial Pain in RCThttps://practicalneurology.com/news/peripheral-nerve-stimulation-reduced-chronic-craniofacial-pain-in-rct/2483874/Treatment with the Freedom Peripheral Nerve Stimulation (PNS) System (Curonix, Pompano Beach, FL) significantly reduced chronic craniofacial pain in a multicenter, randomized controlled clinical trial, which provided Level I evidence for the device’s use. Published in Pain Physician, the